Estimated reading time: 4 minutes · Last updated:
Suki raises $90M in a Series E to accelerate its ambient-AI documentation work and integrations. The company said the round closed on 13 October 2026 with new investors Healthier Capital, Hercules Capital and Crosslink Capital joining backers including Flare Capital Partners and Philips Ventures. Suki’s software captures clinician–patient conversations and turns them into notes for the electronic health record; the company also recently added Ask, an integration that lets clinicians query Wolters Kluwer’s UpToDate. The funding will support an open healthcare AI ecosystem and further product integrations, the company said.
Key takeaways
- Suki raised $90 million in a Series E announced 13 October 2026.
- New investors in Suki’s round include Healthier Capital, Hercules Capital and Crosslink Capital.
- Teladoc Health launched SoloScribe and said SoloVitals will reach general release in December 2026 after limited availability.
- EliseAI raised $350 million in a round that the company said values it at $4 billion.
Table of contents
What Suki’s $90M means for clinician documentation
Suki’s $90 million Series E is intended to speed development of its ambient documentation and wider integrations with clinical systems. The company described its product as capturing conversations between patients and clinicians and converting them into notes for the electronic health record, and it recently launched Ask to let clinicians query Wolters Kluwer’s UpToDate from Suki’s interface. Named participants in the round were Healthier Capital, Hercules Capital and Crosslink Capital, while existing backers including Flare Capital Partners, Hedosophia, Venrock, Zoom Ventures and Philips Ventures also invested.
Suki says the funding will support an open ecosystem for healthcare AI and fuel its AI technology and integrations. For buyers and health systems that already evaluate ambient scribing tools, the round signals continued investor appetite for software that reduces clinician documentation time and ties vendor models to established clinical knowledge sources.
Teladoc adds camera-based vitals and ambient scribing
On 7 October 2026, Teladoc Health rolled out two AI-driven features for its Solo enterprise platform. SoloScribe, which provides ambient documentation functionality, is available now to customers, and SoloVitals, which derives heart rate and respiratory rate from patients’ camera-equipped devices such as smartphones and tablets, is available to select customers and scheduled for general release in December 2026.
Camera-based vital signs and ambient scribing target two different workflow pain points: remote monitoring and clinician note burden. Teladoc’s timeline suggests the vendor will push SoloVitals through broader rollout this winter while keeping SoloScribe in wider use today; how customers accept camera-based vitals will depend on clinical validation and integration with existing monitoring workflows.
Big rounds across the stack: EliseAI and the funding backdrop
EliseAI disclosed a $350 million funding round that the company said values it at $4 billion, led by Andreessen Horowitz and Bessemer Venture Partners with participation from Ontario Teachers’ Pension Plan, Sapphire Ventures and Navitas Capital. EliseAI builds healthcare operations automation for tasks such as scheduling, insurance verification and chart prep, and it said it will use the capital to expand engineering, deployment and sales while opening an engineering hub in San Francisco.
Taken together with Suki’s raise, these moves show venture capital flowing into both clinical-documentation AI and operational automation for health systems. The waves of funding increase competition among vendors and make integration, clinical validation and customer deployment the near-term differentiators.
| Company | Item | Amount / Feature | Date |
|---|---|---|---|
| Suki | Series E funding | $90 million | 13 October 2026 |
| Teladoc Health | Product releases on Solo | SoloScribe available; SoloVitals (camera vitals) general release in December 2026 | 7 October 2026 |
| EliseAI | Growth funding | $350 million; $4 billion valuation | 29 September 2026 |
Where this could go next
The case for
- Increased funding will accelerate integrations and product rollouts, making ambient documentation and camera-based monitoring more widely available to health systems.
- Vendors linking clinical knowledge sources such as UpToDate to documentation tools could improve note accuracy and clinician trust if integration is robust.
The case against
- Broader adoption depends on clinical validation and regulatory comfort with camera-based vitals and ambient-recording workflows.
- Privacy, data governance and reimbursement uncertainty could slow deployments even where the technology is ready.
What to be careful about
- Camera-based vital-sign measurement requires clinical validation and may face regulatory scrutiny before broad acceptance.
- Ambient capture of clinician–patient conversations raises patient privacy and data-handling exposures that health systems must manage.
- Rapid vendor funding and product launches can outpace integration work, creating fragmented implementations across EHRs and workflows.
The bottom line
October 2026’s announcements show two parallel trends: fresh capital for companies building clinician-facing AI and the appearance of camera-based monitoring as a commercial feature. Suki’s $90 million Series E aims to expand documentation integrations and tie clinical knowledge sources into notes, while Teladoc’s Solo features test camera vitals and ambient scribing in live deployments. EliseAI’s large round highlights investor interest in automating administrative workflows. Near term, adoption will hinge on clinical validation, privacy safeguards and how quickly health systems can integrate these tools into electronic health records.
What to watch
- Teladoc’s SoloVitals general release in December 2026 and any published validation studies tied to that rollout.
- Watch for Suki’s ecosystem roadmap and specific launch dates for new integrations; no date has been set.
Frequently asked questions
How much did Suki raise and who joined the round?
Suki raised $90 million in a Series E announced 13 October 2026; new investors named were Healthier Capital, Hercules Capital and Crosslink Capital, and existing backers including Flare Capital Partners and Philips Ventures also participated.
What are Teladoc’s new Solo features and when will SoloVitals be widely available?
Teladoc added SoloScribe, an ambient documentation tool available now, and SoloVitals, which measures heart rate and respiratory rate using camera-equipped devices; SoloVitals was said to be available to select customers and slated for general release in December 2026.
What did EliseAI announce about its funding and valuation?
EliseAI announced a $350 million round that the company said values it at $4 billion, led by Andreessen Horowitz and Bessemer Venture Partners, with participation from Ontario Teachers’ Pension Plan, Sapphire Ventures and Navitas Capital.
Related reading
